immatics is developing cancer drugs that help to activate the self defense mechanisms of the human body.
Our goal is to support patients and physicians with new options in the fight against various cancers.
Our means are synthetic peptides that specifically activate specialized white blood cells of the patient’s immune system against cancer cells.
Our first product for the treatment of kidney cancer, IMA901, has entered a Europe-wide multi-center Phase II clinical trial in 2007. Our second product for the treatment of colorectal cancer, IMA910, has recently entered another large Phase I/II clinical trial and is now open for patient recruitment.
- -- 29 September 2009
immatics appoints Carsten Reinhardt as Chief Medical Officer - Tuebingen, September 29, 2009 – immatics biotechnologies GmbH today announced the appointment of Dr Carsten Reinhardt as ... read more
- -- 29 September 2009
Dr Niels Emmerich (Chief Operating Officer) to leave immatics - Tuebingen, September 29, 2009 – Dr Niels Emmerich has decided to follow new career opportunities and will leave ... read more
- -- 10 August 2009
immatics obtains further important EP patents covering its lead product IMA901 and US patent for MUC-1 peptide - Tübingen and Martinsried/Munich, August 10, 2009 - immatics biotechnologies GmbH today announced ... read more
Renal cell cancer phase II clinical trial
Drug: Peptide-based renal cell cancer vaccine IMA901...read more
Participating countries: Germany, Austria, Switzerland, U.K., Spain, Bulgaria, Hungary, Poland, Romania, Slovakia
Colorectal cancer phase I/II clinical trial
Drug: Peptide-based colorectal cancer vaccine IMA910...read more
Participating countries: Germany, Belgium, U.K., Hungary, Serbia, Latvia, Poland, Romania